 Shares of Amicus Therapeutics Inc. FOLD, -5.11 were up 5.6 in premarket trading on Thursday, the day after the company announced a deal to sell its gene therapy business to ARYA Sciences Acquisition Corp IV ARYD, 0.90 , a special purpose acquisition company sponsored by Perceptive Advisors. Amicus will have a 36 stake in the new company, which will be called Caritas Therapeutics Inc. It will retain commercialization rights to the Fabry and Pompe gene therapy programs. 